A case of effective use of interleukin 6 inhibitors in patients with ankylosing spondylitis with secondary amyloidosis

A case of effective use of interleukin 6 inhibitors in patients with ankylosing spondylitis with secondary amyloidosis

Ineffectiveness of interleukin 6 inhibitors (iIL6), tocilizumab (TCZ) and sarilimumab in ankylosing spondylitis (AS) was shown in randomized clinical trials. However, there is ample evidence that IL6 is actively involved in the pathogenesis of this disease. In addition, the efficacy of iIL6 in patie...

Full description

Saved in:
Bibliographic Details
Main Authors: Sh. F. Erdes, D. G. Rumyantseva, E. M. Agafonova, M. M. Urumova, A. S. Starkova, S. O. Krasnenko
Format: Article
Language:Russian
Published: IMA-PRESS LLC 2021-08-01
Series:Современная ревматология
Subjects:
ankylosing spondylitis
secondary aa-amyloidosis
il6 inhibitors
tocilizumab
Online Access:https://mrj.ima-press.net/mrj/article/view/1168
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items